Skip to main content
. 2022 Nov 22;13:976196. doi: 10.3389/fimmu.2022.976196

Figure 6.

Figure 6

Adoptive transfer of M2 macrophages pre-treated with miR-7083-5p or combination of 5-aza-dC and TSA reduces tumor growth. (A) Tumor volumes after treatment of 4T1 tumor-bearing mice with clodronate and subsequent adoptive transfer of M2 macrophages pre-treated with miR-7083-5p (M2mi) or combination of 5-aza-dC and TSA (M2AT). M1 and M2 macrophages were included as control. (B, C) qRT-PCR analysis of the relative mRNA levels of M2- (B) and M1-type (C) cytokines and markers in tumor tissues after treatments. (D–G) Flow cytometric analysis of the population of CD206+ M2 macrophages and CD86+ M1 macrophages (D), CD11b+Gr1+ MDSCs (E), CD4+ T cells (F), and CD8+ T cells (G) in the tumor tissues after treatments. A+T, combined treatment with 5-aza-dC and TSA. Clo, clodronate. Data represent the mean ± SD. *, P<0.05; **, P<0.01; ***, P<0.001; n.s., not significant (n=3 mice per group), as assessed using one-way ANOVA followed by Tukey’s multiple comparison post-hoc test.